| [1] |
Erratum: kidney disease: improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int suppl. 2017;7:1-59[J]. Kidney Int Suppl, 2017, 7(3): e1.
|
| [2] |
Diana VP. mSphere of influence: It's not me, it's you-how donor factors influence kidney transplant outcomes[J]. mSphere, 2020, 5(1):e00964-e009619.
|
| [3] |
Mahmoud MS, Mohamed A, Sherouk E, et al. Secondary osteoporosis and metabolic bone diseases[J]. J Clin Med, 2022, 11(9):2382.
doi: 10.3390/jcm11092382
URL
|
| [4] |
Nishat T, Priyata D, Jannatun N, et al. Osteoporosis, an inevitable circumstance of chronic kidney disease: A systematic review[J]. Cureus, 2021, 13(10): e18488.
|
| [5] |
Hsu CY, Chen LR, Chen KH. Osteoporosis in patients with chronic kidney diseases: A systemic review[J]. Int J Mol Sci, 2020, 21(18):6846.
doi: 10.3390/ijms21186846
URL
|
| [6] |
Liu C, Li H. Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin d deficiency[J]. Expe Ther Med, 2019, 17(1): 368-372.
|
| [7] |
Yoshiko I, Junichiro JK, Masafumi Fukagawa. Molecular abnormalities underlying bone fragility in chronic kidney disease[J]. BioMed Resear Int, 2017, 2017: 3485785.
|
| [8] |
Hou YC, Lu CL, Lu KC, et al. Mineral bone disorders in chronic kidney disease[J]. Nephrology (Carlton), 2018, 23(Suppl 4): 88-94.
doi: 10.1111/nep.2018.23.issue-S4
URL
|
| [9] |
Hanne SJ, Karel D, Syazrah S, et al. Traditional and non-traditional risk factors for osteoporosis in CKD[J]. Calcif Tissue Int, 2021, 108(4): 496-511.
doi: 10.1007/s00223-020-00786-0
|
| [10] |
Anna K, Karolina S, Karolina I, et al. FGF23: A review of its role in mineral metabolism and renal and cardiovascular disease[J]. Dis Markers, 2021, 17(2021) : 8821292.
|
| [11] |
Sandro M, Giuseppe C, Antonio De P, et al. Bone, inflammation and the bone marrow niche in chronic kidney disease: What do we know?[J]. Nephrol Dial Transplant, 2018, 33(12): 2092-100.
doi: 10.1093/ndt/gfy115
URL
|
| [12] |
Kazu HO, Yoshinori T, Yoshiko S, et al. Serum dickkopf-related protein 1 and sclerostin may predict the progression of chronic kidney disease in Japanese patients[J]. Nephrol Dial Transplant, 2019, 34(8): 1426-1427.
doi: 10.1093/ndt/gfz078
URL
|
| [13] |
Neto R, Pereira L, Magalhães J, et al. Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4[J]. Clin Kidney J, 2021, 14(11): 2401-2408.
doi: 10.1093/ckj/sfab081
pmid: 34754436
|
| [14] |
Saeedeh HH, Mohammad T, Sadegh J. Soy isoflavones and bone health: Focus on the RANKL/RANK/OPG pathway[J]. Biomed Resear Int, 2022: 8862278.
|
| [15] |
Evenepoel P, Opdebeeck B, David K, et al. Bone-vascular axis in chronic kidney disease[J]. Adv Chronic Kidney Dis, 2019, 26(6): 472-483.
doi: 10.1053/j.ackd.2019.09.006
URL
|
| [16] |
Laetitia M, Zineb B, Anteneh A, et al. The roles of RANK/RANKL/OPG in cardiac, skeletal, and smooth muscles in health and disease[J]. Front Cell Dev Biol, 2022, 26(10): 903657.
|
| [17] |
Rizzoli R. Vitamin D supplementation: upper limit for safety revisited?[J]. Aging clinical and experimental research, 2021, 33(1): 19-24.
doi: 10.1007/s40520-020-01678-x
|
| [18] |
Kosaku N, Aiji Y, Ken T. Management of osteoporosis in chronic kidney disease[J]. Intern Med, 2017, 56(24): 3271-3276.
doi: 10.2169/internalmedicine.8618-16
URL
|
| [19] |
Geeta H, Grahame JE, Martine CS, et al. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease[J]. Endocrine, 2021, 73(3): 509-529.
doi: 10.1007/s12020-021-02735-9
pmid: 33974225
|
| [20] |
Pieter E, John C, Serge F, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D[J]. Nephrol Dial Transplant, 2021, 36(1): 42-59.
doi: 10.1093/ndt/gfaa192
URL
|
| [21] |
国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 52-57.
|
| [22] |
Fellype CB, Sérgio GEB. Treatment of osteoporosis in chronic kidney disease[J]. J'Brase Nefrol, 2021, 43(< W>4 Suppl 1): 654-659.
|
| [23] |
Daniel C, Katharina K, Till B, et al. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study[J]. Kidney Blood Pres Res, 2010, 33(3): 221-226.
|
| [24] |
Kao CC, Wu PC, Chuang MT, et al. Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease[J]. Postgrad Med J, 2023, 99(1170):340-349.
doi: 10.1136/postgradmedj-2021-140341
URL
|
| [25] |
Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: A review[J]. Am J Kidney Dis, 2022, 79(3):427-436.
doi: 10.1053/j.ajkd.2021.06.031
URL
|
| [26] |
Mohammad T, Mohammed HM, Negin A, et al. RANKL/RANK/OPG pathway: A mechanism involved in exercise-induced bone remodeling[J]. BioMed Res Int, 2020, 19(2020): 6910312.
|
| [27] |
Khairallah P, Nickolas TL. Updates in CKD-associated osteoporosis[J]. Curr Osteoporos Rep, 2018, 16(6):712-723.
doi: 10.1007/s11914-018-0491-3
pmid: 30353319
|
| [28] |
McKee H, Ioannidis G, Lau A, et al. Correction to: comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients[J]. Osteoporos Int, 2020, 31(5):981.
doi: 10.1007/s00198-020-05381-5
pmid: 32189031
|
| [29] |
Chen CL, Chen NC, Wu FZ, et al. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study[J]. Osteoporos Int, 2020, 31(8):1507-1516.
doi: 10.1007/s00198-020-05391-3
pmid: 32246167
|
| [30] |
Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension[J]. J Bone Miner Res, 2018, 33(2):190-198.
doi: 10.1002/jbmr.3337
pmid: 29105841
|
| [31] |
Broadwell A, Chines A, Ebeling PR, et al. Denosumab safety and efficacy among participants in the freedom extension study with mild to moderate chronic kidney disease[J]. Clin Endocrinol Metab, 2021, 106(2):397-409.
doi: 10.1210/clinem/dgaa851
URL
|
| [32] |
李梅, 章振林, 夏维波. 骨质疏松症药物治疗的必由之路:长程序贯治疗[J]. 中华骨质疏松和骨矿盐疾病杂志, 2021, 14(5): 441-446.
|
| [33] |
Chandra A, Rajawat J. Skeletal aging and osteoporosis: Mechanisms and therapeutics[J]. Int J Mol Sci, 2021, 22(7):3553.
doi: 10.3390/ijms22073553
URL
|
| [34] |
Hara T, Hijikata Y, Matsubara Y, et al. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D[J]. Cochrane Database Syst Rev, 2021, 7(7):CD013424.
|
